Generic placeholder image

Reviews on Recent Clinical Trials

Editor-in-Chief

ISSN (Print): 1574-8871
ISSN (Online): 1876-1038

Commentary

Should SARS CoV-2 Infection be Considered an Independent Risk Factor for Pneumocystis jirovecii Pneumonia? Emerging Data after Two Years of Pandemic from a Single Center Experience

Author(s): Antonio Riccardo Buonomo*, Giulio Viceconte, Biagio Pinchera, Riccardo Scotto, Emanuela Zappulo, Maria Foggia and Ivan Gentile

Volume 17, Issue 3, 2022

Published on: 25 August, 2022

Page: [220 - 222] Pages: 3

DOI: 10.2174/1574887117666220511123826

conference banner
« Previous
[1]
Langford BJ, So M, Raybardhan S, et al. Bacterial co-infection and secondary infection in patients with COVID-19: A living rapid review and meta-analysis. Clin Microbiol Infect 2020; 26(12): 1622-9.
[http://dx.doi.org/10.1016/j.cmi.2020.07.016] [PMID: 32711058]
[2]
Casalini G, Giacomelli A, Ridolfo A, Gervasoni C, Antinori S. Invasive fungal infections complicating COVID-19: A narrative review. J Fungi (Basel) 2021; 7(11): 921.
[http://dx.doi.org/10.3390/jof7110921] [PMID: 34829210]
[3]
Donnelly JP, Chen SC, Kauffman CA, et al. Revision and update of the consensus definitions of invasive fungal disease from the European organization for research and treatment of cancer and the mycoses study group education and research consortium. Clin Infect Dis 2020; 71(6): 1367-76.
[http://dx.doi.org/10.1093/cid/ciz1008] [PMID: 31802125]
[4]
Gentile I, Viceconte G, Lanzardo A, et al. Pneumocystis jirovecii pneumonia in Non-HIV patients recovering from COVID-19: A single-center experience. Int J Environ Res Public Health 2021; 18(21): 11399.
[http://dx.doi.org/10.3390/ijerph182111399] [PMID: 34769913]
[5]
Viceconte G, Buonomo AR, Lanzardo A, et al. Pneumocystis jirovecii pneumonia in an immunocompetent patient recovered from COVID-19. Infect Dis (Lond) 2021; 53(5): 382-5.
[http://dx.doi.org/10.1080/23744235.2021.1890331] [PMID: 33645461]
[6]
Del Corpo O, Butler-Laporte G, Sheppard DC, Cheng MP, McDonald EG, Lee TC. Diagnostic accuracy of serum (1-3)-β-D-glucan for Pneumocystis jirovecii pneumonia: A systematic review and meta-analysis. Clin Microbiol Infect 2020; 26(9): 1137-43.
[http://dx.doi.org/10.1016/j.cmi.2020.05.024] [PMID: 32479781]
[7]
Buonomo AR, Viceconte G, Gentile I. Pneumocystis jirovecii pneumonia in COVID-19: An overlooked clinical entity-Response to “Pneumocystis pneumonia risk among viral acute respiratory distress syndrome related or not to COVID 19”. Crit Care 2021; 25(1): 418.
[http://dx.doi.org/10.1186/s13054-021-03836-7] [PMID: 34872608]

© 2024 Bentham Science Publishers | Privacy Policy